Novartis AG
Novartis Campus
4002 Basel
Switzerland
 
Telephone : +41 61 324 1111
 
 
 
 
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
 
 
 
 
 
 
January 30, 2019
 
 
 
 
 
Re:    Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
 
 
 
Ladies and Gentlemen:
 
 
 
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission on January 30, 2019.
 
 
 
Respectfully submitted,
 
Novartis AG
 
 
 
 
 
/s/ SHANNON THYME KLINGER /s/ HARRY KIRSCH
Shannon Thyme Klinger Harry Kirsch
General Counsel Chief Financial Officer
Novartis Group Novartis Group